Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea · Delayed Price · Currency is KRW 1,912.00
+441.00 (29.98%)
Feb 5, 2026, 3:30 PM KST
Xcell Therapeutics Revenue
Xcell Therapeutics had revenue of 334.59M KRW in the quarter ending September 30, 2025, a decrease of -26.92%. This brings the company's revenue in the last twelve months to 1.36B, down -29.97% year-over-year. In the year 2024, Xcell Therapeutics had annual revenue of 1.93B with 72.11% growth.
Revenue (ttm)
1.36B
Revenue Growth
-29.97%
P/S Ratio
18.68
Revenue / Employee
n/a
Employees
n/a
Market Cap
25.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.93B | 810.45M | 72.11% |
| Dec 31, 2023 | 1.12B | 103.86M | 10.18% |
| Dec 31, 2022 | 1.02B | -946.25M | -48.12% |
| Dec 31, 2021 | 1.97B | 1.43B | 264.00% |
| Dec 31, 2020 | 540.20M | 454.60M | 531.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EASY BIO,Inc. | 465.24B |
| Macrogen | 179.98B |
| Amicogen | 87.97B |
| ORIENT BIO | 59.09B |
| GeneOne Life Science | 30.90B |
| CG Invites | 18.12B |
| ENCell | 5.91B |
| Genexine | 5.81B |